Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States

Open Access

Peer-reviewed

Research Article

Haridarshan Patel,

Affiliation Immensity Consulting, Inc., Chicago, Illinois, United States of America
⨯
Trevor Lissoos,

Affiliation Takeda Pharmaceuticals U.S.A., Inc., Chicago, Illinois, United States of America
⨯
David T. Rubin

* E-mail: drubin@medicine.bsd.uchicago.edu

Affiliation Inflammatory Bowel Disease Center University of Chicago Medicine, Chicago, Illinois, United States of America

http://orcid.org/0000-0001-5647-1723

⨯

Reader Comments (0)

Ulcerative colitis
Is the Subject Area "Ulcerative colitis" applicable to this article?

Thanks for your feedback.
Receptor antagonist therapy
Is the Subject Area "Receptor antagonist therapy" applicable to this article?

Thanks for your feedback.
Corticosteroid therapy
Is the Subject Area "Corticosteroid therapy" applicable to this article?

Thanks for your feedback.
Crohn's disease
Is the Subject Area "Crohn's disease" applicable to this article?

Thanks for your feedback.
Inflammatory bowel disease
Is the Subject Area "Inflammatory bowel disease" applicable to this article?

Thanks for your feedback.
Therapeutic drug monitoring
Is the Subject Area "Therapeutic drug monitoring" applicable to this article?

Thanks for your feedback.
Fistulas
Is the Subject Area "Fistulas" applicable to this article?

Thanks for your feedback.
Surgical and invasive medical procedures
Is the Subject Area "Surgical and invasive medical procedures" applicable to this article?

Thanks for your feedback.